Preventive Asthma Drug Market Outlook 2020
|出版商||RNCOS E-Services Pvt. Ltd.||商品編碼||346849|
|出版日期||內容資訊||英文 45 Pages
|氣喘預防藥的全球市場的展望 Preventive Asthma Drug Market Outlook 2020|
|出版日期: 2015年12月07日||內容資訊: 英文 45 Pages||
現在，全球有約3億名氣喘患者。另一方面，到目前為止的研究開發 (R&D) 活動，有各種抑制氣喘發作的醫藥品開發、上市。全球製藥企業進一步推動研究活動，著手開發氣喘的預防藥。2014年時，全球氣喘預防藥的市場規模估計為220億美元。
本報告提供全球氣喘預防藥的市場相關分析、疾病概要，及主要推動及阻礙市場要素、今後的市場趨勢預測、各產品/各地區的詳細趨勢、市場最新趨勢與發展的方向性、主要企業簡介競爭力 (SWOT分析) 等相關調查。
Asthma is showing high prevalence worldwide. About 300 Million people are suffering from asthma. This is due to continuously deteriorating air quality, which is causing several allergies. In recent years, researchers have explored wide variety of preventive drugs that can delay asthma attacks. These drugs are being highly acknowledged by the doctors and consumers. The practice of prescribing preventive drugs by doctors is gaining momentum in the US, Europe and Asia-Pacific. Foreseeing the demand, several pharma players are shifting their R&D focus towards preventive asthma drugs. Some of the leading players in the pharma industry include Glaxosmithkline, Astrazeneca, Merck, Novartis, Roche, and others. The drugs by these players contributed millions of dollars to their revenue in 2014.
In its latest research, “Preventive Asthma Drug Market Outlook 2020”, RNCOS presents a comprehensive analysis of the industry. The report covers key drivers & challenges, and trends & developments that are peculiar to the drug market. The research includes estimated market figures of 2014, and forecasted numbers till 2020. The market was estimated at US$ 22 Billion in 2014. Our analysts have segmented the preventive asthma drug industry depending on the type of drugs and geographical distribution. A separate section is allotted to the competitive landscape, including the business overview of the key players and their SWOT analysis.
Our research revealed that inhaled corticosteroids were the most popular category of preventers during 2014. Researchers are combining corticosteroids with other form of drugs, such as long acting beta agonists in a single inhaler. The so called “combination therapy” is providing several benefits over the single dose. However, the market is facing few challenges like side-effects posed by such drugs, their high cost and lack of awareness in India, China, and other Middle East & Asia-Pacific countries.
Towards the end, RNCOS has suggested some recommendations to boost the preventers market in the coming future. On the whole, the research contains exhaustive information that will help clients in formulating market strategies and assessing opportunity areas in the preventive asthma drugs industry.